Dipeptidyl peptidase (DPP)-4 inhibitors are the frequently used new category of oral hypoglycemic agents for T2DM due to their ability to improve glycemic control without increasing the risk of hypoglycemia [7]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.